Ensign Peak Advisors’s Amgen AMGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$75.4M Buy
214,379
+28,517
+15% +$10.2M 0.14% 145
2025
Q4
$60.8M Sell
185,862
-40,492
-18% -$12.8M 0.11% 164
2025
Q3
$63.9M Sell
226,354
-84,766
-27% -$24.6M 0.1% 166
2025
Q2
$86.9M Sell
311,120
-106,567
-26% -$30.2M 0.15% 134
2025
Q1
$130M Buy
417,687
+81,632
+24% +$24.1M 0.25% 83
2024
Q4
$87.6M Buy
336,055
+68,990
+26% +$20.5M 0.16% 123
2024
Q3
$86.1M Sell
267,065
-1,895
-0.7% -$620K 0.15% 120
2024
Q2
$84M Sell
268,960
-4,002
-1% -$1.18M 0.15% 117
2024
Q1
$77.6M Sell
272,962
-391,393
-59% -$115M 0.14% 145
2023
Q4
$191M Sell
664,355
-96,069
-13% -$26.2M 0.38% 62
2023
Q3
$204M Buy
760,424
+384,955
+103% +$96.1M 0.44% 53
2023
Q2
$83.4M Sell
375,469
-19,028
-5% -$4.42M 0.17% 116
2023
Q1
$95.4M Sell
394,497
-108,923
-22% -$26.7M 0.21% 98
2022
Q4
$132M Sell
503,420
-4,134
-0.8% -$1.11M 0.3% 85
2022
Q3
$114M Sell
507,554
-6,530
-1% -$1.58M 0.28% 87
2022
Q2
$125M Buy
514,084
+277,374
+117% +$68M 0.3% 81
2022
Q1
$57.2M Buy
236,710
+59,155
+33% +$13.6M 0.12% 162
2021
Q4
$39.9M Buy
177,555
+98,853
+126% +$20.9M 0.08% 221
2021
Q3
$16.7M Sell
78,702
-7,155
-8% -$1.65M 0.03% 339
2021
Q2
$20.9M Sell
85,857
-905
-1% -$223K 0.04% 307
2021
Q1
$21.6M Sell
86,762
-99,457
-53% -$23.7M 0.05% 301
2020
Q4
$42.8M Sell
186,219
-96,353
-34% -$22.2M 0.1% 179
2020
Q3
$71.8M Buy
282,572
+15,465
+6% +$3.83M 0.18% 107
2020
Q2
$63M Sell
267,107
-69,417
-21% -$15.8M 0.17% 111
2020
Q1
$68.2M Buy
336,524
+38,534
+13% +$8.42M 0.23% 88
2019
Q4
$71.8M Buy
+297,990
New +$65.7M 0.19% 97

Other funds holding AMGN

Ensign Peak Advisors's AMGN Position: Q1 2026 in Review

Ensign Peak Advisors increased its Amgen (AMGN) stake by 15% in Q1 2026, buying an estimated $10.2M and bringing the position to 214,379 shares worth $75.4M. The position accounts for 0.14% of the portfolio, ranked #145.

Ensign Peak Advisors first reported a position in AMGN in Q4 2019 and has held it in 26 quarters since. The position peaked at $204M in Q3 2023. 3,127 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.

  • Ensign Peak Advisors held 214,379 shares of Amgen worth $75.4M as of Q1 2026.
  • Ensign Peak Advisors bought 28,517 Amgen shares in Q1 2026, an estimated $10.2M.
  • Amgen made up 0.14% of Ensign Peak Advisors's portfolio in Q1 2026, its #145 holding.
  • Ensign Peak Advisors first reported a position in Amgen in Q4 2019 and has held it in 26 quarters since.
  • Ensign Peak Advisors's Amgen position peaked at $204M in Q3 2023.
  • 3,127 funds tracked by Wall St. Rank held Amgen as of Q1 2026.

Based on Ensign Peak Advisors's 13F filing for Q1 2026, filed 13 May 2026.